This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Agulnik M , Yarber JL , Okuno SH , von Mehren M , Jovanovic BD , Brockstein BE , Evens AM , Benjamin RS
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger)
Annals of Oncology. 2013 Jan;24(1) :257-263
AbstractTo determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of < 1, adequate organ function and had not received any radiation treatment in the last 28 days. Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.
NotesAgulnik, M. Yarber, J. L. Okuno, S. H. von Mehren, M. Jovanovic, B. D. Brockstein, B. E. Evens, A. M. Benjamin, R. S. Genentech/Roche; bevacizumab Genentech/Roche for the clinical research funding support and bevacizumab. 45 Oxford univ press Oxford 058si NALS OF SURGERYnullMiller, KathyMiller, KWang, MolinWang, MLGralow, JulieGralow, JDickler, MauraDickler, MCobleigh, MelodyCobleigh, MPerez, Edith A.Perez, EAShenkier, TamaraShenkier, TCella, DavidCella, DDavidson, Nancy E.Davidson, NE20073572666NEW ENGLAND JOURNAL OF MEDICINEnullSaltz, Leonard B.Saltz, LBClarke, StephenClarke, SDiaz-Rubio, EduardoDiaz-Rubio, EScheithauer, WernerScheithauer, WFiger, ArieFiger, AWong, RalphWong, RKoski, SherylKoski, SLichinitser, MikhailLichinitser, MYang, Tsai-ShenYang, TSRivera, FernandoRivera, FCouture, FelixCouture, FSirzen, FlorinSirzen, FCassidy, JimCassidy, J2008262013JOURNAL OF CLINICAL ONCOLOGY43rd Annual Meeting of the American-Society-of-Clinical-Oncology, JUN 01-05, 2007, Chicago, ILnullTherasse, PEisenhauer, EA20009211J Natl Cancer InstnullPenel, NicolasPenel, NBui, Binh NguyenBui, BNBay, Jacques-OlivierBay, JOCupissol, DidierCupissol, DRay-Coquard, IsabelleRay-Coquard, IPiperno-Neumann, SophiePiperno-Neumann, SKerbrat, PierreKe! Please contact your library administrator, or person(s) responsible for document delivery, to find out more about your organization's policy for obtaining the full text of the above articles. If your organization does not have a current document delivery provider, you can order the document from our document delivery service TS Doc. To order a copy of the article(s) you wish to receive, please go to www.contentscm.com and enter the citation information for each document. A price quote for each item will be given and you will need a credit card to complete your order request. TS Doc customers can purchase the full text of an article using their TS Doc account. Go to www.contentscm.com and login using your TS Doc logon ID and password. Copy & paste the citation into the parser (Order by Citation) or enter the citation information above on the web order form (Order by Form.) A quote will be given for each item and your company will be invoiced as specified in your TS Doc agreement. Product name: TS Doc Customer Service: email@example.com or (800) 603-4367